Loading company…
Biopharmaceutical company developing immunotherapeutic products and tumor-selective therapies for cancer patients.
Xilio Therapeutics, Inc. is a biopharmaceutical company founded in 2016 by Rene Russo and based in Massachusetts, US. Its pipeline includes XTX202, XTX301, XTX401 and XTX101, and it plans to use its funds to advance XTX202 and XTX101 into clinical development. In February 2021 it raised USD 95 million in Series C funding from investors including Atlas Venture, Bain Capital Life Sciences, Deerfield Management and Takeda Ventures. The company listed on the Nasdaq Global Select Market under the ticker XLO in October 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in